Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination refers to a specific treatment arm in a clinical trial conducted by Kelowna General Hospital for the treatment of uncomplicated cellulitis. The regimen consists of oral cephalexin (a first-generation cephalosporin antibiotic), intravenous saline (acting as a placebo for cefazolin), and oral probenecid (or its placebo). Cephalexin works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins. Probenecid is typically used to increase the plasma concentration and prolong the half-life of beta-lactam antibiotics by inhibiting their renal tubular secretion. The trial aimed to determine if oral cephalexin is non-inferior to the standard intravenous cefazolin plus probenecid regimen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cephalexin + saline + probenecid.